DOXY4STICARE - doxycycline for sexually transmitted infections; a comprehensive assessment of antimicrobial resistance and engagement - sexually transmitted infections (STIS) represent a significant…

Active Project Grant Awarded Last action

Award ID
R01AI192204
Recipient
Awarding agency
Obligated
$1,661,248

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 26% complete
Place of performance
New York, NY 10032, USA

Award details come from USAspending.gov.

Description

DOXY4STICARE - doxycycline for sexually transmitted infections; a comprehensive assessment of antimicrobial resistance and engagement - sexually transmitted infections (STIS) represent a significant public health challenge, with increasing prevalence worldwide. Disproportionately affecting young individuals, GAY and bisexual men who have SEX with men (MSM), persons with HIV or on HIV prevention medications, and racial and ethnic minorities, effective prevention strategies are essential. Doxycycline post-exposure prophylaxis (DOXY-PEP) has been shown to reduce bacterial STIS; however, knowledge gaps remain, and there are concerns about engagement, effective use, and the potential antimicrobial resistance consequences. This study proposes a threefold approach to address these questions. (1) create a prospective cohort of 500 participants (300 DOXY-PEP users, 200 eligible non-users as a comparator group) to examine baseline and longitudinal factors mapped to the information-motivation-behavioral skills theoretical framework and identify factors associated with DOXY-PEP care engagement and effective use. (2) collect biological samples from the prospective cohort to evaluate the impact of antimicrobial resistance in persons taking DOXY-PEP using laboratory methods including culture and resistance testing and metagenomics. (3) collect biological samples from up to 100 sexual partners of the cohort to assess the potential for transmission of bacteria between sexual partners using comparative genomics. By addressing these aims, the study will provide valuable insights into the risks, benefits, implementation, and impact of DOXY-PEP, informing future strategies to optimize engagement and maximize STI incidence reduction while minimizing antimicrobial resistance risks.

Transactions

Action Obligated Date
Amendment $0
Amendment $823,785
Original award $837,463

Subawards

Subrecipient Amount Awarded
New York Medical College As Co-Investigator, Qiuhu Shi, PhD, will be responsible for primary data analysis. Dr. Shi has been involved public health related research for more than 20… $23,103
New York Medical College New York Medical College will support “Doxy4STICare - Doxycycline for Sexually Transmitted Infections; A Comprehensive Assessment of Antimicrobial Resistance… $23,103

Quick answers

Who received award R01AI192204?

R01AI192204 was awarded to The Trustees Of Columbia University In The City Of New York by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 4, 2025.

How much is award R01AI192204 worth?

$1,661,248 has been obligated on R01AI192204.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award